Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–7 of 7 results
Advanced filters: Author: Marine Fidelle Clear advanced filters

  • In a phase 2 trial evaluating healthy donor fecal microbial transplantation plus either anti-PD-1 in patients with non-small cell lung cancer or anti-PD-1 and anti-CTLA-4 in patients with melanoma, encouraging efficacy was seen in both cohorts, with responses linked to significantly greater loss of baseline bacterial species.

    • Sreya Duttagupta
    • Meriem Messaoudene
    • Arielle Elkrief
    ResearchOpen Access
    Nature Medicine
    P: 1-14

  • A clinical cohort-based biomarker study in patients with metastatic renal cell carcinoma demonstrates that blood levels of soluble mucosal addressin cell adhesion molecule-1 are prognostic for survival in patients treated with tyrosine kinase inhibitors and immune checkpoint inhibitors and may serve as a surrogate marker for gut dysbiosis based on integrated data from three clinical trials.

    • Carolina Alves Costa Silva
    • Marc Machaalani
    • Laurence Albiges
    ResearchOpen Access
    Nature Medicine
    Volume: 32, P: 671-681

  • Escherichia coli engineered to display cytokines destroy hard-to-treat tumors by boosting the activity of local native and adoptive immune effector cells.

    • Marine Fidelle
    • Laurence Zitvogel
    News & Views
    Nature Biotechnology
    Volume: 43, P: 1246-1248

  • MIND-DC was a randomized, placebo-controlled, phase 3 trial of adjuvant blood-derived natural dendritic cell (nDC)-based therapy in patients with stage III melanoma, showing that nDC-induced immune responses did not translate into survival benefit. Here the authors report that, despite randomization, baseline differences in fecal metagenomics and serum metabolomics profiles between treatment arms might have influenced the clinical outcome of the trial.

    • Carolina Alves Costa Silva
    • Gianmarco Piccinno
    • I. Jolanda M. de Vries
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-16

  • Many studies attempting to identify biomarkers for predicting of immune-checkpoint inhibitor (ICI) efficacy have led to the description of Gut OncoMicrobiome Signatures (GOMS). Several GOMS support an association between oncogenesis and intestinal dysbiosis, and other GOMS are shared between patients with several cancer subtypes and individuals with seemingly unrelated chronic inflammatory disorders. The authors of this Review discuss these patterns as well as the findings from a meta-analysis of GOMS associated with clinical benefit from ICIs, and propose practical guidelines to incorporate GOMS in decision-making in immuno-oncology.

    • Andrew Maltez Thomas
    • Marine Fidelle
    • Laurence Zitvogel
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 20, P: 583-603

  • The ONCOBIOME network has generated new tools to measure dysbiosis and completed numerous trials aimed at modifying the microbiota to enhance cancer treatment; this Review summarizes the key advances and the progress toward translating them into clinical practice.

    • Laurence Zitvogel
    • Lisa Derosa
    • Guido Kroemer
    Reviews
    Nature Medicine
    Volume: 31, P: 1085-1098